Sintilimab: First Global Approval-Reference-Cited by-同舟云学术

Sintilimab: First Global Approval

Published:2019-02 Issue:3 Volume:79 Page:341-346
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hoy Sheridan M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-019-1066-z/fulltext.html

Reference14 articles.

1. Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643–54.

2. Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.

3. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–15.

4. Innovent Biologics. China’s NMPA approves Innovent’s anti-PD-1 antibody Tyvyt® (sintilimab injection) for Hodgkin’s lymphoma [media release]. 26 Dec 2018. http://innoventbio.com/en/#/news/123 .

5. Innovent Biologics. Tyvyt® (sintilimab): Chinese prescribing information. Suzhou: Innovent Biologics; 2019.

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Studying protein–protein interactions: Latest and most popular approaches;Journal of Structural Biology;2024-12

2. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

3. Etoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report;Frontiers in Oncology;2024-08-16

4. Jejunal sarcomatoid carcinoma: A case report and review of literature;World Journal of Gastrointestinal Oncology;2024-08-15

5. Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma;Frontiers in Oncology;2024-07-23